WO2015036643A3 - Marcador para predecir metástasis del cáncer de mama - Google Patents
Marcador para predecir metástasis del cáncer de mama Download PDFInfo
- Publication number
- WO2015036643A3 WO2015036643A3 PCT/ES2014/070699 ES2014070699W WO2015036643A3 WO 2015036643 A3 WO2015036643 A3 WO 2015036643A3 ES 2014070699 W ES2014070699 W ES 2014070699W WO 2015036643 A3 WO2015036643 A3 WO 2015036643A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- breast cancer
- taxane
- metastasis
- marker
- vitro method
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La invención se relaciona con un método in vitro para predecir metástasis en un sujeto diagnosticado con cáncer de mama y tratado con un taxano, con un método in vitro para la selección de pacientes de cáncer de mama que presentan riesgo de desarrollar metástasis tras el tratamiento con taxano y con un método in vitro para el diseño de una terapia personalizada de un sujeto que sufre de cáncer de mama y que está siendo tratado con taxano basados en determinar el nivel de GRP94 y/o FN14. Asimismo, la invención se relaciona con una composición que comprende un taxano y un inhibidor de GRP94 y/o un inhibidor de FN14 y con su uso en el tratamiento de metástasis cerebral.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/021,134 US20160223547A1 (en) | 2013-09-13 | 2014-09-12 | Marker for predicting metastasis of breast cancer |
EP14789584.1A EP3045917A2 (en) | 2013-09-13 | 2014-09-12 | Marker for predicting metastasis of breast cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ESP201331335 | 2013-09-13 | ||
ES201331335 | 2013-09-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2015036643A2 WO2015036643A2 (es) | 2015-03-19 |
WO2015036643A3 true WO2015036643A3 (es) | 2015-06-04 |
Family
ID=51795644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2014/070699 WO2015036643A2 (es) | 2013-09-13 | 2014-09-12 | Marcador para predecir metástasis del cancer de mama |
Country Status (3)
Country | Link |
---|---|
US (1) | US20160223547A1 (es) |
EP (1) | EP3045917A2 (es) |
WO (1) | WO2015036643A2 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7300394B2 (ja) | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害 |
SG11202000132WA (en) | 2017-07-10 | 2020-02-27 | Univ Cornell | Targeting chromosomal instability and downstream cytosolic dna signaling for cancer treatment |
CN113881769B (zh) * | 2021-06-03 | 2023-08-18 | 南京世和基因生物技术股份有限公司 | 脑脊液cfDNA在用于乳腺癌转移诊疗中的用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005000314A1 (en) * | 2003-05-30 | 2005-01-06 | Kosan Biosciences, Inc. | Method for treating diseases using hsp90-inhibiting agents in combination with antimitotics |
WO2005046593A2 (en) * | 2003-11-06 | 2005-05-26 | Celgene Corporation | Methods and compositions using thalidomide for the treatment and management of cancers and other diseases. |
WO2010142651A2 (en) * | 2009-06-10 | 2010-12-16 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge (Idibell) | Method for determining the risk of developing brain metastasis, and a kit to carry out said method |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
US20090186039A1 (en) | 2008-01-18 | 2009-07-23 | Jang Sung-Key | Novel use of grp 94 in virus infection |
US20090324602A1 (en) | 2008-05-15 | 2009-12-31 | Biogen Idec Ma Inc. | Anti-fn14 antibodies and uses thereof |
EP2330100B1 (en) | 2009-11-04 | 2017-01-11 | Emcure Pharmaceuticals Limited | An improved process for preparation of taxane derivatives |
WO2012075327A1 (en) | 2010-12-02 | 2012-06-07 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Methods for treating a tumor using an antibody that specifically binds grp94 |
-
2014
- 2014-09-12 US US15/021,134 patent/US20160223547A1/en not_active Abandoned
- 2014-09-12 EP EP14789584.1A patent/EP3045917A2/en not_active Withdrawn
- 2014-09-12 WO PCT/ES2014/070699 patent/WO2015036643A2/es active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005000314A1 (en) * | 2003-05-30 | 2005-01-06 | Kosan Biosciences, Inc. | Method for treating diseases using hsp90-inhibiting agents in combination with antimitotics |
WO2005046593A2 (en) * | 2003-11-06 | 2005-05-26 | Celgene Corporation | Methods and compositions using thalidomide for the treatment and management of cancers and other diseases. |
WO2010142651A2 (en) * | 2009-06-10 | 2010-12-16 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge (Idibell) | Method for determining the risk of developing brain metastasis, and a kit to carry out said method |
Non-Patent Citations (1)
Title |
---|
TOSONI A ET AL: "Chemotherapy in breast cancer patients with brain metastases: Have new chemotherapic agents changed the clinical outcome?", CRITICAL REVIEWS IN ONCOLOGY / HEMATOLOGY, ELSEVIER SCIENCE IRELAND LTD., LIMERICK, IE, vol. 68, no. 3, 1 December 2008 (2008-12-01), pages 212 - 221, XP025780311, ISSN: 1040-8428, [retrieved on 20080612], DOI: 10.1016/J.CRITREVONC.2008.04.004 * |
Also Published As
Publication number | Publication date |
---|---|
US20160223547A1 (en) | 2016-08-04 |
EP3045917A2 (en) | 2016-07-20 |
WO2015036643A2 (es) | 2015-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016501728A1 (en) | Anti-angiogenesis therapy for the treatment of ovarian cancer | |
WO2015189345A3 (en) | Compositions and methods for the diagnosis and treatment of bone fractures and disorders | |
EP4335931A3 (en) | Therapeutic and diagnostic methods for cancer | |
MX2020010947A (es) | Metodos de tratamiento de enfermedad de alzheimer. | |
PH12015501744A1 (en) | Therapeutic and diagnostic target for cancer comprising dll3 binding reagents | |
PH12020551683A1 (en) | Biomarkers for graft-versus-host disease | |
EP4356960A3 (en) | Biomarkers and methods of treating pd-1 and pd-l1 related conditions | |
WO2016077366A8 (en) | Therapeutic and diagnostic methods for il-33-mediated disorders | |
WO2014143807A3 (en) | Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders | |
PH12016502167A1 (en) | Hdl theraphy markers | |
MX2018004170A (es) | Biomarcadores relacionados con enfermedades mediadas por interleucina-33 (il-33) y usos de los mismos. | |
BR112015017403A2 (pt) | biomarcadores de terapia de combinação de anti-tnf e anti-il17 para doença inflamatória | |
BR112016007864A2 (pt) | método para a prognose e tratamento de metástase de câncer | |
EP4279127A3 (en) | Growth differentiation factor 15 as biomarker for metformin | |
WO2015116729A3 (en) | Anti-cd37 antibody and anti-cd20 antibody combination therapy for treatment of b-cell malignancies and disorders | |
MX2018001831A (es) | Biomarcadores para el tratamiento de alopecia areata. | |
WO2016030334A3 (en) | Methods, agents and compositions for treatment of inflammatory conditions | |
MX2015012444A (es) | Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos. | |
MX2016017097A (es) | Biomarcadores para la respuesta a inhibidores del mejorador del homologo 2 de zeste (ezh2). | |
MX2020006388A (es) | Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea. | |
WO2015036643A3 (es) | Marcador para predecir metástasis del cáncer de mama | |
BR112014018374A8 (pt) | Método para predizer a resposta d eum paciente com câncer, kit, anticorpo, método para o tratamento do câncer e composição farmacêutica | |
MX2021011799A (es) | Antagonistas de semaforina 4d para usarlos en la terapia contra el cancer. | |
WO2013171777A3 (en) | Use of trop-2 as predictive marker of response to anti-tumor therapy based on inhibitors of cd9, akt and molecules of the tetraspanin signalling network | |
WO2014169011A3 (en) | Methods for treating immune diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14789584 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15021134 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2014789584 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014789584 Country of ref document: EP |